ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1848

A Single-Center Retrospective Study of Thrombotic Microangiopathy

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Bustos, Aulio Elias, Westchester Medical Center Health Network, Valhalla, New York, United States
  • Chugh, Savneek S., Westchester Medical Center Health Network, Valhalla, New York, United States
  • Gupta, Sanjeev, Westchester Medical Center Health Network, Valhalla, New York, United States
  • Deval, Neha, Westchester Medical Center Health Network, Valhalla, New York, United States
  • Jafri, Firas, Westchester Medical Center Health Network, Valhalla, New York, United States
  • Khosla, Jagjit, Westchester Medical Center Health Network, Valhalla, New York, United States
  • Mangaroliya, Vrunda, Westchester Medical Center Health Network, Valhalla, New York, United States
  • Kore, Shruti, Westchester Medical Center Health Network, Valhalla, New York, United States
Background

Thrombotic microangiopathies (TMAs) are a rare group of clotting disorders of various origin, including infectious, idiopathic, autoimmune or drug-induced. This group shares common clinical manifestations that include low red blood cell and platelet counts. Although the disease is rare but treatable if clinician is aware about its manifestations. To increase the awareness and understand the disease better we conducted a retrospective study to characterize and assess TMAs in our institution

Methods

An observational retrospective study of patients with a diagnosis of TMA at Westchester Medical Center in the past 5 years was conducted. Data was collected from electronic medical records. Demographic, clinical and therapeutic variables were extracted, tabulated and analyzed

Results

A total of 43 patients with a diagnosis of TMA were identified and included in the study. The cohort had a mean age of 39.9 years; 20 were male and 23 females. As shown in Table 1. Thrombotic thrombocytopenia purpura (TTP) (n=14, 32%), systemic lupus erythematosus (SLE) (n=5, 11.6%), and hemolytic uremic syndrome (HUS) (n=5, 11.6%) are the most common etiologies. Other identifiable etiologies were atypical HUS (9%), use of calcineurin inhibitors (9%), acute myeloid leukemia (4.6%). About 6.9% cases didn’t have any identifiable cause (6.9%). Patients with TTP had a mean age of 48 years, mean platelet count of 17 k/mm3, and most were female (71%). Fifty-seven percent had hematuria, 21% proteinuria and 85% had schistocytes in the blood smear

Conclusion

Most common cause of thrombotic Microangiopathies is TTP which is what we found in our institution. It is essential to aware about the manifestation of this disease since early recognition and prompt treatment is the key for better outcome

Table 1
EtiologyTTPSLEHUS
Number of cases1455
Mean age, years483016
Mean platelets count (k/mm3)17105.453.8
Hematuria, %5780100
Proteinuria, %2180100
Schistocytes, %8560100

TTP, thrombotic thrombocytopenia purpura; SLE, systemic lupus erythematosus; HUS, hemolytic uremic syndrome